Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047190 · ClinicalTrials.gov registry record · Phase 2
Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia
A Phase 2 study of Primary Myelofibrosis and Polycythemia Vera, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00047190: Completed Phase 2 study of Primary Myelofibrosis and Polycythemia Vera, sponsored by National Cancer Institute (NCI).
NCT00047190 is a Phase 2 study of Primary Myelofibrosis and Polycythemia Vera that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants, below the 120-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00047190, a Phase 2 study of Primary Myelofibrosis and Polycythemia Vera, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase II trial to study the effectiveness of tipifarnib in treating patients who have myelofibrosis with myeloid metaplasia. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
Primary Outcome
Confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG tipifarnib
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2002-08 |
| Phase | Phase 2 |
What the finished NCT00047190 record still lists
NCT00047190 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 120-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (71% lower).
The record links to 3 conditions, with Primary Myelofibrosis appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00047190 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00047190 about?
NCT00047190 is a clinical study titled "Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia". Phase II trial to study the effectiveness of tipifarnib in treating patients who have myelofibrosis with myeloid metaplasia. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
What is the current status of trial NCT00047190?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2002-08.
What conditions does trial NCT00047190 study?
This clinical trial studies the following conditions: Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia.
What interventions are being tested in trial NCT00047190?
The interventions under investigation include: laboratory biomarker analysis (OTHER), tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00047190?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00047190 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00047190's enrollment target sits among peer trials
35 20th of 30 higher than 11 of 30 other Primary Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
RECRUITING · Phase 2
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Study of Canakinumab in Patients With Myelofibrosis
RECRUITING · Phase 2
-
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
RECRUITING · Phase 2
-
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
RECRUITING · Phase 2
-
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia